Search

Objective: We aimed to investigate the roles of inflammatory parameters, including neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), lymphocyte/monocyte ratio (LMR), and C-reactive protein/albumin ratio (CAR), in predicting disease recurrence in patients with stage IIA (T3N0M0) high microsatellite instability and microsatellite-stable colon cancer who had no risk factors associated with relapse.Materials and methods: We evaluated 155 patients with colon cancer followed in 3 hospitals in Turkey between February 2009 and March 2020. These patients had stage IIA disease and had no risk factors associated with relapse. None of the patients received adjuvant chemotherapy. NLR, PLR, LMR, and CAR parameters were retrospectively obtained from laboratory results at the time of diagnosis, and their associations with disease recurrence were assessed.Results: Over a median follow-up period of 38 months (range: 4-98 months), 11 of the 155 patients experienced relapse or developed metastases. Multivariate Cox analyses revealed that NLRs of ≥3.12 (hazard ratio [HR]: 0.041, 95% confidence interval [CI]: 0.048-0.826, p = 0.006) and CARs of ≥0.027 (HR: 0.199, 95% CI: 0.004-0.404, p = 0.026) were independent prognostic markers predicting relapse. The median 5-year recurrence-free survival rate of patients with NLRs of ≥3.12 at the time of diagnosis was 88.0%; this rate was 100% in patients with NLRs of

Background: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of MCC cases in Turkey. Materials and methods: The patients diagnosed with MCC between 1999 and 2018 at twenty different centers in Turkey were included in the study. Patient and tumor characteristics and adjuvant and metastatis treatment outcomes were analyzed retrospectively. Results: The median age of totally 89 patients was 70 (26-93). The most common primary location was lower limbs (n = 29, 32.5%). Immunohistochemically, CK20 positivity was present in 59 patients (66.3%). Only two patients had secondary malignancy. The majority of the patients (n = 76, 85.4%) were diagnosed at the localized stage. Surgery was performed for all patients in the early stage, and adjuvant radiotherapy or/and chemotherapy was applied to 52.6% (n = 40) of nonmetastatic patients. The median follow-up was 29 months. Recurrence developed in 21 (27.6%) of the 76 patients who presented with local or regional disease. Two-year disease-free survival (DFS) was 68.1% and 5-year DFS was 62.0% for localized stage. The 5-year DFS was similar for patients receiving adjuvant treatment (chemotherapy, radiotherapy, or sequential chemoradiotherapy) and without adjuvant therapy (P > 0.05). Two-year overall survival in patients who presented with localized disease was 71.3% and 18.5% in metastatic patients (P < 0.001). In the metastatic stage, platinum/etoposide combination was the most preferred combination regimen. Median progression-free survival (PFS) in first-line chemotherapy was 7 months (95% confidence interval: 3.5-10.5 months; standart error: 1.78). Conclusions: Although MCC is rare in Turkey, the incidence is increasing. Gender, CK20 status, tumor size, lymph node involvement, and adjuvant treatment were not associated with recurrence.

Aim: Desmoid tumors (DTs) are very rare tumors that grow gradually anywhere in the body they are locally aggressive, but with a low potential for metastasis. Very good results can be obtained with different combinations of treatments, such as surgery, chemotherapy, hormonal therapy, tyrosine kinase inhibitor therapy and radiotherapy. Case series even with a small number of patients are of considerable importance as experience with DTs limited. Therefore, in this study, we aimed to discuss the management of DTs with our case series. Materials and Methods: In our study, 15 patients with DT, who were treated and followed up between January 2005 and January 2020 in two hospital medical oncology departments in Turkey, were evaluated. Results: The median age of diagnosis of the patients was 34 (range 18-48) years. Seven (46.6%) of the patients were female and eight (53.4%) were male. Seven (46.6%) of the tumors were located in the abdominal wall, four (26.7%) were in the limbs three (20%) were in the intra-abdominal area, and one (6.7%) was in the chest wall. In terms of resectability, 14 (93.3%) were resectable, and one (6.7%) was unresectable. The five-year overall survival rate was 73.85%, and the average disease-free survival time until relapse was 35 (range 15-83) months in patients who relapsed. The two- and five-year relapse-free survival rates were 90.9% and 66.5%, respectively. The median progression-free survival (PFS) for first-line treatment was 25 (range 8.6-89.8) months. The median PFS for second-line treatment was seven (range 4.3-38.0) months. In the one patient who received third-line treatment, PFS was 8.3 months. Conclusion: Frequent relapses in DTs are still the biggest problem in treating this disease. Although surgery treatment is the main treatment method used in desmoid tumors, controversy about adjuvant therapy after surgery continues, and new treatment modalities are required.

A 70 year-old women admitted to our hospital with a swelling and discharge of the right inguinal site. Biopsy results was consisted with malignant melanoma. Imaging of thorax and abdomen showed metastatic disease. After first-line temozolamide treatment, palliative radiotherapy was applied to primary site because of progression. After detection of BRAF-V600E mutation, vemurafenib treatment was initiated. Treatment response to vemurafenib was very good partial response after second months of the treatment. Although locally progression of the left lung was seen after fifth months of therapy, partial response remained on the other sites, she was still on the treatment with vemurafenib., Yetmiş yaşında kadın sağ inguinal bölgede akıntılı şişliği olması üzerine başvurdu. Lezyon biyopsisi malign melanomla uyumluydu. Toraks ve batın görüntülemelerinde metastaz bulguları mevcuttu. Birinci basamak temozolomid sonrası lezyon bölgesinde progresyon nedeni ile palyatif radyoterapi uygulandı. BRAF-V600E mutasyonu nedeni ile vemurafenib başlandı. Tedavinin ikinci ayında çok iyi kısmi yanıt elde edildi. Tedavinin 5. ayında sol akciğerde lokal progresyon izlenirken diğer bölgelerde kısmi yanıtı devam ediyordu. Palyatif radyoterapi sonrası vemurafenib tedavisine devam edildi.

Fifty four year-old men with a family history of colon cancer diagnosed multiple colonic poliposis upon colonoscopy. Since pathology of colonic biopsy yielded adenocarcinoma, together with a family history of colon cancer, total colectomy was done. Histopathology of colectomy showed multisentric colonic adenocarcinoma together with grade 1 neuroendocrine tumor of the appendix. Our patient was unique because of the rarity of the coincidence of colonic adenocarcinoma and appendix neuroendocrine tumor.

Esophageal carcinoma ranks 6 th among cancer-releated deaths. It commonly metastasize to the lung, liver and bone. Breast metastasis of esophageal cancer is rarely seen and therefore we aimed to present this case. A 54-year old woman who diagnosed with locally advanced squamous cell esophageal cancer received chemo-radiotherapy. In follow-up, widespread metastasis, including breast, was detected.

nadir olgu bildirimleri vardır (2). Dünya sağlık örgütü akciğer kanseri sınıflamasında BHK; adenokarsinom, yassı hücreli karsinom ve büyük hücreli sınıflandırılmaktadır (3). Bizde BHK’nın böbrek dışındaki dokularda nadir de olsa görülebileceğini ve akılda tutulması gerektiğini böyle bir olgu ile göstermek istedik